Document is current
Any future updates will be listed below
-
Authors
Fleischmann, Roy M. https://orcid.org/0000-0002-6630-1477
Strand, Vibeke
Feist, Eugen
Lisitsyna, Tatiana
Sparks, Jeffrey A.
Nasonov, Evgeny
Samsonov, Mikhail
Grishin, Sergey
Egorova, Alina
Kuzkina, Sofiya
Smolen, Josef S.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02760368 at ClinicalTrials.govnct02760407 at ClinicalTrials.govDocuments that mention this clinical trial
THU0176 OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: RESULTS FROM THE DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE III STUDY (CREDO-1)
https://doi.org/10.1136/annrheumdis-2020-eular.2102
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
https://doi.org/10.1007/s40744-026-00852-3
OP0021 OLOKIZUMAB, MONOCLONAL ANTIBODY AGAINST IL6, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: EFFICACY AND SAFETY RESULTS OF PHASE III CREDO-1 STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.1688
POS0646 EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1550
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
https://doi.org/10.1136/ard-2023-225473
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
https://doi.org/10.1136/annrheumdis-2021-219876
nct02760433 at ClinicalTrials.govDocuments that mention this clinical trial
POS1071 THE IMPACT OF COMORBIDITIES ON THE EFFICACY OF IL-6 INHIBITOR OLOKIZUMAB COMPARED TO ADALIMUMAB
https://doi.org/10.1136/annrheumdis-2023-eular.2475
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
https://doi.org/10.1007/s40744-026-00852-3
POS0646 EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1550
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
https://doi.org/10.1136/ard-2023-225473
OP0063 OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS PATIENTS INADEQUATELY CONTROLLED BY METHOTREXATE (MTX-IR): RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED TRIAL, CREDO 2
https://doi.org/10.1136/annrheumdis-2022-eular.1977
nct03120949 at ClinicalTrials.govDocuments that mention this clinical trial
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
https://doi.org/10.1007/s40744-026-00852-3
POS0646 EFFECT OF OLOKIZUMAB ON THE NEUTROPHIL-LYMPOCYTE RATIO IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2024-eular.1550
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
https://doi.org/10.1136/ard-2023-225473
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
https://doi.org/10.1136/ard-2022-222630
POS0291 OLOKIZUMAB IMPROVED PATIENT REPORTED OUTCOMES IN TNF INCOMPLETE RESPONDER (TNF-IR) RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED TRIAL, CREDO 3
https://doi.org/10.1136/annrheumdis-2022-eular.1990
Documents that mention this clinical trial
POS0640 OLOKIZUMAB IMPROVED PATIENT REPORTED OUTCOMES IN MTX AND TNF INCOMPLETE RESPONDER RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE LONG TERM EXTENTION TRIAL
https://doi.org/10.1136/annrheumdis-2023-eular.1848
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
https://doi.org/10.1007/s40744-026-00852-3
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
https://doi.org/10.1136/ard-2023-225473
POS0645 LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
https://doi.org/10.1136/annrheumdis-2022-eular.1743
- License Information
-
More Information
Article History
Received: 8 December 2025
Accepted: 30 March 2026
First Online: 16 May 2026
Declarations
:
: Roy M Fleischmann is an Editor-in-Chief of Rheumatology and Therapy . Roy M Fleischmann was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Roy M Fleischmann reports consulting fees for AbbVie, Almirall, Anaptys, Artiva Biotherapeutics, Atomwise, Biohaven Pharmaceuticals, BMS. Cyoxone, Deep Cure, Dren Bio, ECOR, Eisai, Galvani, Gates Bio, Genentech, Gilead, GSK, Halia, Immunovant, ImmuneMed, InventisBio, Istesso, Janssen, Janux, Eli Lilly, MSD, Monte Rosa, Overland, Novartis, Pfizer, Roche, RPharm, Synact, TPG, UCB, Vyne and Xencor; Vibeke Strand reports consulting fees for Abbvie, Amgen, Andera, Arthrosi, Artiva, Astra Zeneca, Autolus, Bayer, BMS, Boehringer Ingelheim, Catalys, Contura, Cullinan, Fate Rx, Fortress Biotech, Gate Biosciences, GSK, Inmedix, Kiniksa, Lipum, Longitude Capital, MED Institute, Novartis, Pacira, RAPT, Royalty Pharma, Samsung Bioepis, Sanofi, Scipher, Setpoint, Sobi, Soleil, Spherix, Synact, Takeda, Wield and Zoe, and participation for AstraZeneca DSMB. Eugen Feist reports grants or research support from Eli Lilly, Novartis, Pfizer, Alfasigma; serving as a consultant for AbbVie, Eli Lilly, Galapagos, Medac, Novartis, Sanofi, Sobi, R-Pharm and Alfasigma. Tatiana Lisitsyna reports consulting fees for R-Pharm. Jeffrey A Sparks reports grants/research support from National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute, Rheumatology Research Foundation, Arthritis Foundation, R Bruce and Joan M Mickey Research Scholar Fund, Gordon and Llura Gund Foundation, Bristol Myers Squibb, Boehringer Ingelheim, Johnson & Johnson, and Sonoma Biotherapeutics; and serving as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius Kabi, Gilead, Inova Diagnostics, Johnson & Johnson, Merck, MustangBio, Novartis, Optum, Pfizer, ReCor, Sana, Sobi and UCB. Evgeny Nasonov has nothing to disclose. Mikhail Samsonov, Sergey Grishin, Alina Egorova and Sofiya Kuzkina are employees of R-Pharm. Josef S. Smolen reports grants/research support from AbbVie, BMS, Celgene, Chugai, Eli Lilly, Gilead, Janssen, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB; and serving as a consultant for AbbVie, BMS, Celgene, Chugai, Eli Lilly, Gilead, Janssen, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB.
: The trials were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and approved by the Institutional Review Board or Ethics Committee at each center. “R-Pharm”, as the study sponsor, obtained permission to use all the scales/questionnaires within the studies. All patients provided written informed consent. The list of sites are provided with the primary articles as electronic supplementary material files.
